Navigation Links
Team-based approach improves diabetes care
Date:2/7/2008

PHILADELPHIA, February 7, 2008 Due to the success of the first three years of the American College of Physicians (ACP) and the American College of Physicians Foundation (ACPF) Diabetes Initiative, the program has received additional funding from Novo Nordisk Inc. to continue the initiative for an additional two years through December 2009.

The results of the first three years of our efforts confirm that optimal diabetes care requires a team effort, says Vincenza Snow, MD, FACP, director of clinical programs and quality of care at ACP. We are excited to have the opportunity to continue producing programs and products that will improve the health and quality of life for people with diabetes.

Launched in 2005 and funded by an unrestricted educational grant from Novo Nordisk, as part of its Changing Diabetes(sm) initiative, the ACP and ACPF Diabetes Initiative offers educational tools and practice-based, team-oriented training for physicians, patients, and health care teams.

The goals of the initiative include increasing awareness of the gap between current practice and acceptable standards of diabetes care among internists; increasing internists awareness of what constitutes high quality, evidence-based diabetes care; and providing educational tools to improve diabetes treatment.

Practice-Based, Team-Oriented Training Results

To date, 60 team participants from 19 physician practices caring for a total of 1,300 patients have participated in ACPs Closing the Gap module for diabetes, a program that seeks to close the gap between clinical evidence and best practices and the care actually provided in a physicians office. The practice-based, team-oriented program trains teams - usually an internist, a nurse, and a staff assistant - to improve the quality of care for patients with chronic diseases.

This team-based approach has resulted in statistically significant improvements in many clinical measures such a
'/>"/>

Contact: Steve Majewski
smajewski@acponline.org
215-351-2514
American College of Physicians
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related medicine news :

1. Health care incentive model offers collaborative approach
2. Free will takes flight: how our brains respond to an approaching menace
3. New approaches to reduce scarring
4. Research Links TV/Video Game Playing With Child Obesity; Health Experts Back a New Approach
5. New Poll Shows Public Distrusts Flawed Healthcare Approach Favored by Governor and Speaker in AB 8
6. Nuclear medicine approach can be first choice for excluding pulmonary embolism in young women
7. Blue Cross Blue Shield of Michigan Offers New Approach to Customer Group Wellness
8. New Seminar Series from Activator Methods Teaches Doctors a Unique Approach to Improving Nations Chiropractic Care: Focus on the Patients
9. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
10. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
11. Potential new approach to treat cognitive impairments in schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 2China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 3Perceptive Informatics Introduces Greater Convergence Between EDC and RTSM Solutions in Its eClinical Suite 2Perceptive Informatics Introduces Greater Convergence Between EDC and RTSM Solutions in Its eClinical Suite 3Perceptive Informatics Introduces Greater Convergence Between EDC and RTSM Solutions in Its eClinical Suite 4Perceptive Informatics Introduces Greater Convergence Between EDC and RTSM Solutions in Its eClinical Suite 5TOPAZ Technologies Introduces Biosafety Software Solution 48428 1TOPAZ Technologies Introduces Biosafety Software Solution 48428 2TOPAZ Technologies Introduces Biosafety Software Solution 48428 3As Sleep Improves Grades Seem to Go Up 48427 1As Sleep Improves Grades Seem to Go Up 48427 2MDS Nordion Begins to Manufacture Cardiac Imaging Agent 48425 1MDS Nordion Begins to Manufacture Cardiac Imaging Agent 48425 2MDS Nordion Begins to Manufacture Cardiac Imaging Agent 48425 3